SLC30A8 polymorphism and type 2 diabetes risk: Evidence from 27 study groups
Received 30 July 2009; received in revised form 21 October 2009; accepted 16 November 2009. published online 19 February 2010. Corrected Proof
Abstract
Background and aims
Intense research has been performed to identify the genetic risk factors in type 2 diabetes, and a single nucleotide polymorphism (SNP) in SLC30A8 (rs13266634) was reported to be associated with type 2 diabetes mellitus. However, published data on the association between SLC30A8 polymorphism and the risk of type 2 diabetes were inconsistent. Therefore, we conducted this meta-analysis to derive a more precise estimation of the relationship.
Methods and results
We searched PubMed through October 2009 to identify all relevant papers. Odds ratios (ORs) and 95% confidence intervals (CIs) were extracted under an additive genetic model. In the current meta-analysis, we identified a total of 27 groups including 42,609 cases and 69,564 controls. In analyses of the case–control studies by ethnicity, the results indicated that SLC30A8 polymorphism was related to elevate risks of type 2 diabetes both in Europeans (OR=1.15, 95% CI 1.11–1.18, P<0.001) and Asians (OR=1.15, 95% CI 1.11–1.19, P<0.001). Next, we separated hospital-based case–control studies from population-based case–control studies, however, there was no apparent difference between population-based case–control study groups (OR=1.15, 95% CI 1.12–1.17, P<0.001) and hospital-based case–control study groups (OR=1.16, 95% CI 1.07–1.25, P<0.001).
Conclusion
Our present meta-analysis provided evidence that SLC30A8 (rs13266634) C allele carriers could elevate the risk of type 2 diabetes, especially in Europeans and Asians.
aDepartment of Endocrinology, Drum Tower Clinical Medical College of Nanjing Medical University, Nanjing, Jiangsu Province, China
bDepartment of Pharmacy, the Affiliated Wuxi Hospital for Maternal and Child Health Care of Nanjing Medical University, Wuxi, Jiangsu Province, China
cDepartment of Endocrinology, Affiliated Drum Tower Hospital, Medical College of Nanjing University, Nanjing, Jiangsu Province, China
Correspondence to: Dalong Zhu, Department of Endocrinology, Drum Tower Clinical Medical College of Nanjing Medical University, 321 Zhongshan Road, Nanjing, 210008, Jiangsu Province, China. Tel./Fax: +86 25 83105302.
1 Drs Y.L. Jing, Q.M. Sun and Y. Bi contributed equally to this work.
ABSTRACT
=